AgeCare ExoMask Pro and AgeCare ExoSerum Pro have both been rated ERL 5 by the company under tiptop’s ATDS enterprise framework. This is the highest level on the current 0–5 scale. We also publish the level definitions to explain the criteria behind this enterprise evaluation in full.
ERL measures evidence readiness
ERL stands for Evidence Readiness Level. We use it to organize stages from concept definition through identity characterization, stability, delivery, human confirmation and continuing management.
| Level | Definition | Main requirements |
|---|---|---|
| ERL 0 | Concept defined | Initial market and ethical screening; target location, method of use and draft claims |
| ERL 1 | Identity characterized | Material identity, finished-product critical quality attributes and preliminary method suitability |
| ERL 2 | Stable and releasable | Stage-appropriate stability, packaging compatibility and release evaluation |
| ERL 3 | Delivery demonstrated | Layer-specific quantification and spatial localization of the finished product in suitable skin or scalp models |
| ERL 4 | Confirmed in humans | Safety and human local exposure or performance aligned with intended objectives |
| ERL 5 | Reproducible and market-ready | Support from three batches, shelf-life support, external replication, claim review and post-market monitoring |
The table lists framework requirements. The company assigned ERL 5 to the two current products within this framework. It is an enterprise evidence rating, not certification by a government or international organization, and not a ranking of efficacy strength.
We apply the weakest-link principle
Material identity, final formulation, release and delivery, and human results need to correspond. ATDS emphasizes the weakest link so that evaluation covers the whole evidence chain and extensive information at one stage does not substitute for work at another.
The mask and serum likewise have their own product documentation. ExoMask Pro’s human use evaluation and the separate patch tests for both products are presented for their respective test subjects. A rating does not change the product or conditions to which a result originally applies.
The rating follows a specific product version
We require ERL to be tied to a specific version. Major changes to formulation, packaging, manufacturing site, critical processes or applicable conditions should trigger a review of the evidence and reassessment of the rating.
Publishing ERL is part of explaining our enterprise evaluation approach. When sharing study results, we will continue to identify the relevant test subject, conditions and time points. The extent of underlying information made public depends on each actual disclosure. The full rating framework appears in ATDS 2026.